Japanese mid-size drugmaker Otsuka Pharmaceutical (TYO: 4578) has inked a deal with ShapeTX, a specialist in programmable medicines.
ShapeTX is using artificial intelligence and RNA to tackle a variety of genetic diseases.
The multi-target collaboration will be focused on the development of intravitreally-delivered adeno-associated viruses (AAVs) for ocular diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze